Impact of sarcopenia on anthracycline-related cardiotoxicity in adult cancer patients: a systematic review and exploratory meta-analysis
Introduction. Sarcopenia may increase vulnerability to anthracycline-related cardiac toxicity (ARCT), but evidence remains limited. We evaluated whether sarcopenia or low skeletal muscle mass is associated with ARCT in adult cancer patients. Material and methods. A systematic review and meta-analysis was performed in accordance with the PRISMA 2020 and MOOSE guidelines. PubMed, Scopus, Google Scholar, and Cochrane-CENTRAL were searched through May 2026. Eligible studies enrolled adults receiving predominantly anthracycline-based chemotherapy with objective muscle assessment and cardiac or cardiorespiratory outcomes. Estimates reported as hazard ratios (HRs) were pooled using a random-effects model. Results. Five studies were included (n = 742); two cohorts (n = 491) were eligible for meta-analysis. Sarcopenia prevalence ranged from 10.2% to 27.1%. Low skeletal muscle mass was associated with a higher risk of ARCT [hazard ratio (HR) = 2.31, Wald 95% confidence interval (CI) 1.07–5.00; p = 0.034; I² = 60%; τ² = 0.19]. Some qualitative evidence also linked lower muscle mass or poorer muscle quality with greater cardiac functional decline. Conclusions. Baseline muscle assessment may help identify patients at increased risk of ARCT. These exploratory findings require validation before guiding cardio-oncology surveillance.
Authors
- Jacek Jafra
- Joanna Socha (ORCID: https://orcid.org/0000-0002-3758-5511)
- Jacek Gabryel
- J GABRYEL
- Kamil Alijew (ORCID: https://orcid.org/0009-0000-2817-6102)
- Barbara D. Huras
Institutions
- Jan Długosz University (PL)
Publication Details
- Journal
- Nowotwory Journal of Oncology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5603/njo.113391
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00